Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Inventory: 2020-2025

Historic Inventory for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $18.9 million.

  • Oncology Institute's Inventory rose 8683.95% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 8683.95%. This contributed to the annual value of $10.0 million for FY2024, which is 2660.48% down from last year.
  • Latest data reveals that Oncology Institute reported Inventory of $18.9 million as of Q3 2025, which was up 8683.95% from $15.8 million recorded in Q2 2025.
  • Oncology Institute's 5-year Inventory high stood at $18.9 million for Q3 2025, and its period low was $6.4 million during Q4 2021.
  • Moreover, its 5-year median value for Inventory was $10.8 million (2023), whereas its average is $11.3 million.
  • Its Inventory has fluctuated over the past 5 years, first tumbled by 2660.48% in 2024, then skyrocketed by 8683.95% in 2025.
  • Oncology Institute's Inventory (Quarter) stood at $6.4 million in 2021, then skyrocketed by 43.85% to $9.3 million in 2022, then skyrocketed by 47.69% to $13.7 million in 2023, then fell by 26.6% to $10.0 million in 2024, then skyrocketed by 88.09% to $18.9 million in 2025.
  • Its Inventory stands at $18.9 million for Q3 2025, versus $15.8 million for Q2 2025 and $12.3 million for Q1 2025.